NEWS
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
Alector announced disappointing results from its INVOKE-2 Phase 2 trial of AL002 for early Alzheimer's disease. The drug failed to meet its primary endpoint of slowing disease progression and showed no significant effects on secondary endpoints or biomarkers. While AL002 achieved target engagement, it did not demonstrate treatment benefits and showed ARIA-related safety concerns. Following these results, Alector is discontinuing the long-term extension study and reducing its workforce by 17%. The company will focus on other programs, including the INFRONT-3 Phase 3 trial of latozinemab and PROGRESS-AD Phase 2 trial of AL101/GSK4527226. With $457.2 million in cash reserves, Alector expects runway through 2026.
Alector announced disappointing results from its INVOKE-2 Phase 2 trial of AL002 for early Alzheimer's disease. The drug failed to meet its primary endpoint of slowing disease progression and showed no significant effects on secondary endpoints or biomarkers. While AL002 achieved target engagement, it did not demonstrate treatment benefits and showed ARIA-related safety concerns. Following these results, Alector is discontinuing the long-term extension study and reducing its workforce by 17%. The company will focus on other programs, including the INFRONT-3 Phase 3 trial of latozinemab and PROGRESS-AD Phase 2 trial of AL101/GSK4527226. With $457.2 million in cash reserves, Alector expects runway through 2026.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2914Followers
108Following
30KVisitors
Follow